Home › Employers › Nitto Avecia Pharma Services, Inc.
Nitto Avecia Pharma Services, Inc.: H-1B salaries and sponsorship
Nitto Avecia Pharma Services, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $61,547.
Does Nitto Avecia Pharma Services, Inc. sponsor H-1B visas?
Nitto Avecia Pharma Services, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Jul 22, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Microbiologist | 3 | $59,415 |
| Validation Engineer | 1 | $129,169 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $57,283 |
| FY2024 | 2 | $95,358 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Validation Engineer | $129,169 Level III | Irvine, CA | Jul 22, 2024 | Jan 12, 2025 | Certified |
| Microbiologist | $61,547 Level I | Irvine, CA | May 15, 2023 | Oct 1, 2023 | Certified, then withdrawn |
| Microbiologist | $61,547 Level I | Irvine, CA | Apr 24, 2023 | Oct 1, 2023 | Withdrawn |
| Microbiologist | $57,283 Level I | Irvine, CA | Apr 5, 2023 | Oct 1, 2023 | Certified, then withdrawn |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).